Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Influencers on TikTok have been banned after they were found to be promoting drugs like Ozempic and Mounjaro through their social media ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

A 28-year-old man who started using the injectable medication on Saturday (7 June) has opened up on his experience so far ...

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...